I-Mab ADR (IMAB)

$4.63 -0.01 (-0.22%)
Market Cap 378.09M
Revenue (ttm) 0.00
Net Income (ttm) -22.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,517,300
Avg Vol 1,822,668
Day's Range N/A - N/A
Shares Out 81.66M
Stochastic %K 22%
Beta 1.45
Analysts Strong Sell
Price Target $8.60

Company Profile

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to resear...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
TheRealShortSqueezy
TheRealShortSqueezy Nov. 4 at 2:24 PM
$ONCY Advancing Toward a Platform Immunotherapy in GI Cancers 🧬 📰 Fresh Press Release November 4 : Oncolytics Biotech has established a Gastrointestinal Tumor Scientific Advisory Board to guide pelareorep’s clinical and regulatory strategy across pancreatic, colorectal, and anal cancers. Inaugural Members: ➡️ Dr. Sanjay Goel ➡️ Dr. Deva Mahalingam ➡️ Dr. Dirk Arnold These leading oncology experts have been directly involved in pelareorep based clinical trials. Why it matters: This move reinforces Oncolytics’ mission to position pelareorep as the first true platform immunotherapy in gastrointestinal oncology. With seasoned leadership, expanding clinical validation, and the creation of this world-class advisory board, Oncolytics Biotech is steadily converting scientific promise into commercial potential. 📈 Technical Snapshot: - Support: $1.08 - Breakout levels: $1.19 ➡ $1.33 ➡ $1.42 ➡ $1.47 ➡ $1.51 Communicated Disclaimer: http://bit.ly/4qzOlZb Sector Peers: $GNLX $IMAB $DBVT
2 · Reply
Stocksman45
Stocksman45 Nov. 4 at 12:55 AM
$IMAB https://finance.yahoo.com/news/novabridge-subsidiary-visara-assigns-exclusive-081500758.html
0 · Reply
4th_and_50
4th_and_50 Oct. 31 at 5:06 PM
$IMAB $NBP.X should have changed name to $SNM.X Smoke ‘N Mirrors, but it was taken
0 · Reply
grizzly3
grizzly3 Oct. 30 at 6:40 PM
$FDMT: $IMAB tried the name change to $NBP.X — still sank. Cosmetic changes don’t defy gravity.
0 · Reply
grizzly3
grizzly3 Oct. 30 at 6:25 PM
$IMAB changing its name to $NBP.X won’t change its fate. You can repaint the house, but the cracks in the foundation are still there.
0 · Reply
Yusufkadiani
Yusufkadiani Oct. 30 at 5:52 PM
$IMAB what’s happening with this?
0 · Reply
DARKP00L
DARKP00L Oct. 29 at 1:43 PM
$IMAB 09:20 on Oct. 29 2025 I-Mab Changes Name To NovaBridge Biosciences; To Trade Under New Name, NBP Ticker, Effective Oct. 30 #tradeideas
1 · Reply
sgtcw1
sgtcw1 Oct. 28 at 3:01 PM
$IMAB
0 · Reply
Stocksman45
Stocksman45 Oct. 24 at 8:14 PM
$IMAB https://www.tipranks.com/news/company-announcements/i-mab-reports-positive-phase-i-results-for-givastomig-in-gastroesophageal-cancer
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 9:44 AM
BTIG updates rating for I-MAB ( $IMAB ) to Buy, target set at 9.
0 · Reply
Latest News on IMAB
No data available.
TheRealShortSqueezy
TheRealShortSqueezy Nov. 4 at 2:24 PM
$ONCY Advancing Toward a Platform Immunotherapy in GI Cancers 🧬 📰 Fresh Press Release November 4 : Oncolytics Biotech has established a Gastrointestinal Tumor Scientific Advisory Board to guide pelareorep’s clinical and regulatory strategy across pancreatic, colorectal, and anal cancers. Inaugural Members: ➡️ Dr. Sanjay Goel ➡️ Dr. Deva Mahalingam ➡️ Dr. Dirk Arnold These leading oncology experts have been directly involved in pelareorep based clinical trials. Why it matters: This move reinforces Oncolytics’ mission to position pelareorep as the first true platform immunotherapy in gastrointestinal oncology. With seasoned leadership, expanding clinical validation, and the creation of this world-class advisory board, Oncolytics Biotech is steadily converting scientific promise into commercial potential. 📈 Technical Snapshot: - Support: $1.08 - Breakout levels: $1.19 ➡ $1.33 ➡ $1.42 ➡ $1.47 ➡ $1.51 Communicated Disclaimer: http://bit.ly/4qzOlZb Sector Peers: $GNLX $IMAB $DBVT
2 · Reply
Stocksman45
Stocksman45 Nov. 4 at 12:55 AM
$IMAB https://finance.yahoo.com/news/novabridge-subsidiary-visara-assigns-exclusive-081500758.html
0 · Reply
4th_and_50
4th_and_50 Oct. 31 at 5:06 PM
$IMAB $NBP.X should have changed name to $SNM.X Smoke ‘N Mirrors, but it was taken
0 · Reply
grizzly3
grizzly3 Oct. 30 at 6:40 PM
$FDMT: $IMAB tried the name change to $NBP.X — still sank. Cosmetic changes don’t defy gravity.
0 · Reply
grizzly3
grizzly3 Oct. 30 at 6:25 PM
$IMAB changing its name to $NBP.X won’t change its fate. You can repaint the house, but the cracks in the foundation are still there.
0 · Reply
Yusufkadiani
Yusufkadiani Oct. 30 at 5:52 PM
$IMAB what’s happening with this?
0 · Reply
DARKP00L
DARKP00L Oct. 29 at 1:43 PM
$IMAB 09:20 on Oct. 29 2025 I-Mab Changes Name To NovaBridge Biosciences; To Trade Under New Name, NBP Ticker, Effective Oct. 30 #tradeideas
1 · Reply
sgtcw1
sgtcw1 Oct. 28 at 3:01 PM
$IMAB
0 · Reply
Stocksman45
Stocksman45 Oct. 24 at 8:14 PM
$IMAB https://www.tipranks.com/news/company-announcements/i-mab-reports-positive-phase-i-results-for-givastomig-in-gastroesophageal-cancer
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 9:44 AM
BTIG updates rating for I-MAB ( $IMAB ) to Buy, target set at 9.
0 · Reply
Stocksman45
Stocksman45 Oct. 23 at 5:11 PM
$IMAB Phase 3 drug 2026: VIS-101, to be acquired by Visara, a newly formed I-Mab subsidiary, under the new business model, is a bifunctional biologic targeting VEGF-A and ANG2, currently in Phase 2 development VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, and a more potent molecule that could potentially provide more durable treatment benefits for patients with wet AMD, DME, and retinal vein occlusion (RVO) than current standard of care. VIS-101 has completed initial safety and dose-escalation studies in both the US and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.
0 · Reply
Caresto
Caresto Oct. 23 at 2:57 PM
$IMAB NASDAQ +0.55%, XBI +0.23%, IMAB -4.56%. Others climb, IMAB sinks. That’s not random — that’s traders walking away. Rebrands don’t fix fundamentals. They just tell you the story stopped working.
0 · Reply
XaviersLessons
XaviersLessons Oct. 23 at 5:54 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $SKLZ $BTSG $IMAB $NRG Watchlist \
0 · Reply
ursus_horribilis
ursus_horribilis Oct. 23 at 2:20 AM
$FDMT Notice how caronte keeps pumping the same losing tickers — $IMAB, $OPEN, $TNYA — all downtrending plays. Classic bot behavior: hype without logic, same script everywhere. Block the noise and focus on real analysts like ReturnOfEsquire and Caresto.
0 · Reply
caronte
caronte Oct. 23 at 2:13 AM
$FDMT stay long you can find the activity of such bots also on $IMAB , $OPEN , $TNYA . always bearish, exaggerating and dramatizing any negative performance and always changing username. mute them and their bs.
0 · Reply
ursus_horribilis
ursus_horribilis Oct. 22 at 7:12 PM
$IMAB If -7% on a down day hurts, wait till the real correction starts. No catalyst, no floor — just faith and hope. Good luck holding that. 📉
0 · Reply
ursus_horribilis
ursus_horribilis Oct. 18 at 6:07 PM
$IMAB The SEC Rule 201 (aka "Up-Tick Rule") has been triggered and the related exchanges have implemented a short sale restriction in accordance with their policies. Short selling is still permitted when the SEC Rule 201 criteria are met. Short sale restriction is in effect from Oct 17, 06:39 to Oct 20, 17:00 PST - — translation: selling pressure is real and momentum is bearish. SSR is damage control, not strength. SSR only slows shorts. The dead cat bounce already happened — more downside likely. The trend remains bearish with no clear catalysts and heavy uncertainty around the Hong Kong IPO + rebrand plan.
0 · Reply
ursus_horribilis
ursus_horribilis Oct. 17 at 6:39 PM
$IMAB Rebrand + upcoming IPO screams financing need, not growth. Analyst upgrades often show up right before dilution to attract new buyers. Read between the lines, not the headlines.
1 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 6:19 PM
BTIG has updated their rating for I-MAB ( $IMAB ) to Buy with a price target of 9.
0 · Reply
Stocksman45
Stocksman45 Oct. 17 at 3:50 PM
$IMAB Jefferies ups IMAB target to $10 today.
0 · Reply
Stocksman45
Stocksman45 Oct. 17 at 3:49 PM
$IMAB I-Mab plans to rebrand as NovaBridge Biosciences and pursue a dual listing with a Hong Kong IPO while maintaining its NASDAQ presence, according to Jefferies.
0 · Reply
Stocksman45
Stocksman45 Oct. 17 at 3:13 PM
$IMAB Upgrade and modern info…. https://www.investing.com/news/analyst-ratings/imab-stock-price-target-raised-to-10-by-jefferies-on-rebranding-new-asset-93CH-4294078
0 · Reply